Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Crucell Terug naar discussie overzicht

PB-Antilichamen tegen H5N1 ontdekt

145 Posts
Pagina: 1 2 3 4 5 6 ... 8 »» | Laatste | Omlaag ↓
  1. [verwijderd] 27 september 2007 23:04

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Published: 23:00 27.09.2007 GMT+2 /HUGIN /Source: Crucell N.V. /AEX: CRXL /ISIN: NL0000358562

    Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virus. The antibody provides immediate protection and neutralizes the broadest range of H5N1 strains.

    Leiden, The Netherlands, September 27, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced the discovery of a set of human monoclonal antibodies against H5N1. These results, demonstrating the potential of human monoclonal antibodies for pandemic preparedness, were presented today at the 5th International Bird Flu Summit held in Las Vegas, Nevada.

    A total of twenty one human monoclonal antibodies were discovered. These were found to be able to neutralize the H5N1 virus of avian influenza, which currently presents a global threat. The most potent of the antibodies was shown to neutralize the broadest range of H5N1 strains that have emerged between 1997 and 2004. This antibody may therefore provide a powerful tool in pandemic preparedness. In addition, this antibody prevents flu, in pre-clinical models, when given twenty four hours before a challenge with a lethal dose of highly pathogenic H5N1 virus. When given three days after infection, it also was shown to prevent death and cure the disease.

    "Our discovery of potent human monoclonal antibodies against a number of different H5N1 pandemic flu types, provide proof of concept that antibodies are a serious alternative to vaccination or antiviral treatment", said Dr. Jaap Goudsmit, Chief Scientific Officer of Crucell. "What is most encouraging is the fact that these antibodies are not only able to prevent infection, but also open the possibility to treat infected individuals. Treatment with this antibody provides an instantaneous antiviral response, which is an advantage over the delayed immune response after (prepandemic) vaccination."

    The set of monoclonal antibodies, which was produced by Crucell researchers using phage display and Crucell PER.C6® technology, showed the potential to neutralize distinct H5N1 viruses, A/Vietnam/11994/04, A/Hong Kong/213/03 and A/Hong Kong/156/97. The antibodies apparently recognize a part of the viral membrane protein that is present among all H5N1 viruses tested. The most potent neutralizing antibody was tested in pre-clinical models for the ability to protect against infection with the highly pathogenic A/Hong Kong/97 H5N1 virus and was also tested for its ability to stop the development of the disease caused by this virus. When the monoclonal antibody was given in a pre-clinical model, one day prior to infection with the H5N1 virus, it resulted in full protection against infection. Treatment with the antibody up to three days after infection, resulted in 100% survival and cure of the disease.

    About Pandemic Influenza

    Influenza is a highly infectious virus which spreads easily from person to person. In a pandemic, a new and more virulent virus infectious for humans arises with the potential to cause severe disease and high mortality. H5N1 Viruses isolated from wild and domestic birds and from humans since the outbreaks in Hong Kong separate in distinct genetic groups (clade and subclades) of closely related viruses. Clade 1 virus circulated in Cambodia, Thailand and Viet Nam and caused infections in humans in 2004 and 2005. Clade 2 viruses circulated in China and Indonesia in 2003 -2004 and spread to the Middle East, Africa and Europe in 2005 and 2006.



    About Crucell
    Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit www.crucell.com.

  2. forum rang 10 voda 27 september 2007 23:11

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 92586

      Gegeven: 22738

    •    Aantal posts: 382.808

    Dat is rap Redpoint. Staat nu ook op de Crucell site. Hoe is het mogelijk om 11.00 uur s'ávonds?
    AB!
  3. miekemuis 27 september 2007 23:15

    • miekemuis

      Lid sinds: 18 mrt 2004

      Laatste bezoek: 12 nov 2024

    • Aanbevelingen

      Ontvangen: 82

      Gegeven: 1002

    •    Aantal posts: 315

    AB Redpoint, zo juist voor het slapengaan...

    Morgen allen gezond weer op en hopelijk met een wat hogere koers de week eindigen met dit nieuws. Op dit moment al 7 aanbevelingen (je ziet, er is nog interesse in Crucell door de "aanhangers")

    Slaapwel
  10. forum rang 10 voda 27 september 2007 23:27

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 92586

      Gegeven: 22738

    •    Aantal posts: 382.808

    Al 14 ab's? Zit iedereen te wachten op goed nieuws of zo :-)
  11. [verwijderd] 27 september 2007 23:34

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    After Hours
    Time (ET) After Hours
    Price After Hours
    Share Volume
    17:26 $ 20.85 150
    17:26 $ 21 400
    17:26 $ 21.15 100
    17:08 $ 20.15 200
    16:16 $ 19.929 100

    Hit 'm Hard!

    100% genezing.
    Developed in the Netherlands for mankind!
  14. forum rang 10 voda 27 september 2007 23:42

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 92586

      Gegeven: 22738

    •    Aantal posts: 382.808

    Is dit eerder gebeurt om zo laat nog een PB te "lanceren"?
    Waar is Flosz? (Ja, weg, dat weet ik) :-(
  17. diederique 27 september 2007 23:44

    • diederique

      Lid sinds: 01 mrt 2004

      Laatste bezoek: 03 okt 2024

    • Aanbevelingen

      Ontvangen: 913

      Gegeven: 218

    •    Aantal posts: 8.547

    latest news on biotech stocks in Market Watch:

    Trading higher, U.S.-listed shares of Crucell NV

    CRXL 19.90, +0.50, +2.6%) hopped 2% to $20.85.

    The Dutch biotech company said its researchers have discovered a monoclonal antibody that appears to be effective against the H5N1 strain of avian influenza. The data will be presented at a medical conference late this month in Las Vegas.

    Val Brickates Kennedy is a reporter for MarketWatch in Boston.
  18. [verwijderd] 27 september 2007 23:45

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Japies schreef:

    After Hours
    Time (ET) After Hours
    Price After Hours
    Share Volume
    17:26 $ 20.85 150
    17:26 $ 21 400
    17:26 $ 21.15 100
    17:08 $ 20.15 200
    16:16 $ 19.929 100

    Hit 'm Hard!

    100% genezing.
    Developed in the Netherlands for mankind!
    In case you are wondering, I am here. I am still amused that there are some who think I am a basher in any sense except I hate incompetence, especially of upper management. Always loved Jaap, who seems to carrying this company on his shoulders.

    The after hours "Bid" price on E-Trade is now $22.50, with the "ask" price of $25.00

  19. aossa 27 september 2007 23:45

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 07 feb 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.621

    quote:

    Japies schreef:

    100% genezing H5N1.
    Trots voert bij mij de boventoon wat Crucell uit Nederland te bieden heeft voor de mensheid.
    Super.
    En zeker als men weet dat ze daar in de 20e eeuw nog op klompen liepen ;-)

    Gefeliciteerd noorderburen !

    Volare ... Cantare ... Ohhhh Oh Oh
145 Posts
Pagina: 1 2 3 4 5 6 ... 8 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.196
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.516
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.651
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.995
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.322
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.715
AMG 971 133.053
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 483
Antonov 22.632 153.605
Aperam 92 14.918
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.568
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.989
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390

Macro & Bedrijfsagenda

  1. 07 februari

    1. Aperam Q4-cijfers
    2. Orange Belgium Q4-cijfers
    3. Crédit Agricole Q4-cijfers (Fra)
    4. TotalEnergies Q4-cijfers (Fra)
    5. Novo Nordisk Q4-cijfers (Dee)
    6. Industriële productie december (Dld)
    7. Handelsbalans december (Dld)
    8. Harley-Davidson Q4-cijfers (VS)
    9. Banengroei en werkloosheid januari (VS) Banengroei: 170K, werkloosheid: 4,1%, uurlonen: +3,8% YoY volitaliteit verwacht
    10. Consumentenvertrouwen (Universiteit v Michigan) februari vlpg (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda